The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 24 February 2026•Updated 24 February 2026•

1 min read

Larimar’s FDA Breakthrough Designation for Ataxia Drug Includes Adult and Pediatric Patients

Key Facts

1The U.S. FDA granted Breakthrough Therapy Designation (BTD) to nomlabofusp for the treatment of Friedreich’s ataxia (FA).

3 months ago

Version History

Version 13 months ago

What changed: The update clarifies that the FDA Breakthrough Therapy Designation covers both adult and pediatric populations, specifying the patient demographics included in the regulatory milestone.

Larimar Therapeutics (Nasdaq: LRMR) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its lead drug candidate, nomlabofusp, for the treatment of Friedreich’s ataxia (FA). Crucially, the company confirmed that the designation covers both adult and pediatric patient populations, broadening the potential impact of the therapy. This regulatory status is designed to expedite the development and review of drugs intended to treat serious conditions. The FDA's decision was supported by clinical data and alignment on using skin frataxin (FXN) levels as a surrogate endpoint for accelerated approval. Larimar intends to submit a Biologics License Application (BLA) in June 2026, targeting a commercial launch in the U.S. during the first half of 2027. This milestone significantly de-risks the development process and enhances the company's path toward commercialization, serving as a positive catalyst for biotech investors.